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Abstract
Background: Acutely admitted medical patients are often fragile and in risk of future surgery. The biomarker soluble
urokinase plasminogen activator receptor (suPAR) is a predictor of readmission and mortality in the acute care setting.
We aimed to investigate if suPAR also predicts acute surgery, which is associated with higher mortality than elective
surgery, and if it predicts post-operative mortality.
Methods: A retrospective registry-based cohort study of 17,312 patients admitted to an acute medical unit in Denmark,
from 18 November 2013 until 30 September 2015. The first admission with available suPAR was defined as the index
admission, and patients were followed via national registries until 1 January 2016. The risk of acute surgery during the
entire follow-up period as well as the 90-day post-operative mortality risk was modeled by Cox regression analyses
adjusted for sex, age, C-reactive protein, and Charlson Comorbidity Index (Charlson Score).
Results: Acute surgery was carried out on 2404 patients (13.9%) after a median of 45 days (interquartile range 5–186)
following the index admission. Patients receiving acute surgery had higher baseline suPAR compared with patients
receiving elective- or no surgery (p < 0.0001). The hazard ratio (HR) for acute surgery was 1.50 (95% confidence interval
(CI): 1.42–1.59) for every doubling of the suPAR level in the adjusted Cox regression analysis. Death within
90 days occurred in 439 (18.3%) patients receiving acute surgery, and the adjusted HR for post-operative
mortality was 1.73 (95% CI: 1.52–1.95).
Discussion: Elevated levels of suPAR in acutely admitted medical patients were independently associated with
increased risk of future acute surgery as well as with 90-day post-operative mortality.
Trial registration: This retrospective registry-based cohort study was approved by the Danish Health and
Medicines authority (reference no. 3–3013-1061/1). All processing of personal data followed national
guidelines, and the project was approved by the Danish Data Protection Agency (reference no. HVH-2014-018,
02767).
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Background
Patients admitted for an acute medical condition (acute
medical patients) are at high risk of readmission and
mortality after discharge [1]. In addition, these patients
may undergo acute surgery, either during the primary
admission or later during a readmission. Acute surgery
is associated with higher morbidity and mortality com-
pared with elective surgery [2–4]. The reasons for the
increased mortality are multifactorial, but in some cases
acute surgery can be an expression of critical illness in
patients with more advanced stages of disease [5]. Acute
hospitalization creates an opportunity to identify pa-
tients at high risk of acute surgery. Early recognition of
the need of surgery could reduce the number of surgical
procedures performed under acute circumstances, which
may in turn reduce associated morbidity and mortality.
Furthermore, identification of patients who are at high
risk of post-operative mortality may aid in the decision
on when to operate and in planning resources for post-
operative care.
Soluble urokinase plasminogen activator receptor
(suPAR) is an unspecific marker of immune activation and
reflects the overall inflammatory state of an individual.
Elevated plasma levels of suPAR are strongly associated
with development, presence, and progression of a broad
range of diseases [6–8], such as cardiovascular diseases
and diabetes [9–11], certain types of cancer [9, 12–14],
chronic and acute kidney disease [15, 16], and infectious
diseases [17–19].
Among acutely admitted medical patients, elevated
suPAR is an independent risk marker associated with in-
tensive care unit admissions, readmissions, and mortality
[1, 20].
In this study, we aimed to investigate if suPAR measured
at admission can predict the risk of future acute surgery
and post-operative mortality following acute surgery in a
large cohort of acutely admitted medical patients.
Methods
Study design and setting
This retrospective, registry-based study was carried out
at Copenhagen University Hospital Amager and
Hvidovre, Hvidovre, Denmark, investigating patients
who were admitted and had blood samples drawn at the
Acute Medical Unit (AMU) from 18 November 2013
until 30 September 2015. Since 18 November 2013,
suPAR was routinely analyzed in all AMU patients as
part of the standard blood samples taken at admission.
Data on a subgroup of this population was previously
described by Rasmussen et al. [1]. The index admission
was defined as the first admission during this period
where suPAR was measured. The patients were followed in
national registries for minimum 90 days from the index ad-
mission through 31 December 2015. The Danish personal
civil registration number (CPR number) was used to link
patient data from national registries with laboratory data
from the electronic hospital database LABKA. The Danish
National Patient Registry (NPR) contains information on all
hospital admissions, including dates of admission and
discharge, registered diagnoses, and surgical proce-
dures performed. Hospital admission contacts in the
NPR with less than 5 h apart were considered to
belong to the same hospital admission, while contacts
with more than 5 h apart were considered to belong
to separate admissions. The survival status was ex-
tracted from the Civil Registration System.
Selection of participants
Patients were included if they had standard blood samples
analyzed during their admission to the AMU. Children,
obstetrical-, gynecological-, gastroenterological-, and acute
surgical patients were admitted to specialized acute
departments and were therefore not included. Patients
were excluded if no suPAR measurement was available or
if follow-up via national registries was not possible.
Outcomes
The primary outcome was surgery, defined as a patient
having any surgical procedure registered in the NPR
during an admission in the follow-up period: acute sur-
gery was defined as an admission containing at least one
acute surgical procedure; elective surgery was defined as
an admission containing only planned, and no acute,
surgical procedures. Thus, if a patient had both an elect-
ive and an acute surgical procedure registered within the
same admission, it was defined as acute surgery. The
distinction between acute and elective surgical proce-
dures was made based on a variable in NPR that indi-
cates whether the admission for a given surgical contact
is acute or planned. Surgical procedures were stratified
according to specialty, using the classification from the
Danish national Healthcare Classification System (SKS).
Smaller surgical procedures, such as lumbar- and ascites
puncture and needle biopsies, and investigative proce-
dures, such as endoscopies, were included in the analyses
as surgery. A separate analysis excluding patients who
only had minor surgery or endoscopies was carried out as
well. Surgery types with less than 50 cases were compiled
into the category “Other” (endocrine-, ophthalmological-,
head and neck-, oral-, breast-, and tissue transplantation
surgical procedures). Cancer-related surgery was defined
as any surgical procedure for the primary diagnosis cancer
(ICD-10 C00-C97). It should be noted that a patient can
be in more than one surgical specialty.
The secondary outcome was all-cause mortality. When
comparing mortality between non-surgical and surgical
patients, we used mortality rates per person-year during
the entire follow-up period. Patients who received
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surgery were categorized as non-surgical patients until
the day of surgery; after that their time at risk was calcu-
lated for acute or elective surgery, respectively, until
death or end of follow-up. This was done to prevent
immortality bias. When comparing mortality between
surgical specialties, we used 90-day post-operative
mortality calculated from the first day of surgery.
Measurements
Plasma levels of suPAR were analyzed as part of the
standard blood samples at the Department of Clinical
Biochemistry as previously described [1]. Briefly, suPAR
was measured daily during weekdays in singlets using
the suPARnostic® AUTO Flex ELISA on a Siemens
BEP2000 analyzer according to the manufacturer’s instruc-
tions (ViroGates A/S, Birkerød, Denmark). C-reactive pro-
tein (CRP) was measured using a COBAS 6000 analyzer
(Roche Diagnostics, Mannheim, Germany).
Charlson score
The Charlson Comorbidity Index (Charlson score) [21],
was calculated using all diagnoses registered in the NPR
for the index admission and in the 2 years prior to the
index admission. The Charlson Score is a weighted
scoring system, rating the number and severity of chronic
comorbidities, including chronic kidney disease among
others. We used a SAS macro (developed by Ken Turner
and Charles Burchill) based on ICD-10 diagnoses to calcu-
late the Charlson score [22], using the revised weighting
by Quan et al. [23].
Data analysis
Continuous data are presented as medians with inter-
quartile range (IQR). Differences in continuous variables
were tested by Student’s t-test or Wilcoxon’s two-sample
test, and categorical variables were tested by Chi-
squared test. The correlation between suPAR and CRP
was calculated using Kendall rank correlation coefficient.
The risk of acute surgery and post-operative mortality
was modeled by Cox regression as a function of log2-
transformed suPAR adjusted for sex, age, CRP, and
Charlson score. A second analysis was made including
creatinine in the adjustment. We used a combined end-
point for acute surgery, using death and elective surgery
as competing risks. In the Cox regression analysis of
post-operative mortality, the number of days to surgery
was also included as an explanatory variable to adjust
for differences in time from suPAR measurement to
surgery. We also tested for an interaction between the
suPAR level and time from suPAR analysis to surgery.
The results are presented as hazard ratios (HRs) with
95% confidence intervals (CIs).
The risk of acute surgery and 90-day post-operative
mortality according to suPAR level was presented in
cumulative incidence plots and Kaplan-Meier plots, re-
spectively. suPAR values were stratified in 3 ng/ml inter-
vals to ensure that the results were less dependent on
the specific cohort and thereby comparable with other
patient cohorts. The log-rank test was used to compare
mortality or risk of acute surgery between suPAR strata
in the cumulative incidence and Kaplan-Meier plots.
SAS Enterprise Guide 7.1 (SAS Institute, Cary, North
Carolina, USA) and R 3.0.3 (R Foundation for Statistical
Computing, Vienna, Austria) were used for statistical




The cohort consisted of 20,193 patients who were admit-
ted to the AMU for an acute medical condition. A total of
2881 were excluded (Fig. 1), leaving 17,312 patients for
analysis. Baseline characteristics are shown in Table 1.
Fig. 1 Flow diagram of included patients. AMU, Acute Medical Unit;
CPR, civil registration number; NPR, National Patient Registry, suPAR,
soluble urokinase plasminogen activator receptor
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The median follow-up time for all included patients was
394 days (IQR 218–583). During follow-up, 3768 (21.8%)
patients had surgical procedures performed. Of these,
2404 (63.8%) were acute (Table 2). The median time from
suPAR measurement at the index admission until surgery
was 74 days (IQR 9–218); 45 days (IQR 5–186) for acute
surgery and 118 days (IQR 37–275) for elective surgery.
suPAR is associated with acute surgery
Patients receiving acute surgery were older and had higher
suPAR and CRP levels at the index admission compared
with non-surgical patients (Table 2). Furthermore, the
median Charlson score was higher, showing an increased
prevalence of comorbidities among acute surgical patients
(Table 2). Similarly, patients who underwent elective
surgery were older and had higher suPAR and Charlson
score compared with non-surgical patients (Table 2). For
the entire population, suPAR and CRP were positively
correlated (Kendall’s tau b 0.36, p < 0.0001).
In the Cox regression model adjusted for sex, age,
CRP, and Charlson score, suPAR was associated with
acute surgery during follow-up, with a HR of 1.50 (95%
CI: 1.42–1.59, p < 0.0001) for every doubling in suPAR.
When including creatinine in the adjustment, the HR
was 1.45 (95% CI: 1.37–1.54, p < 0.0001).
Furthermore, we carried out a sub-analysis excluding 761
patients that exclusively had minor surgical procedures
performed (minor surgery and endoscopies). In this sub-
analysis, adjusted for sex, age, CRP and Charlson score,
every doubling in suPAR was associated with a HR of 1.37
(95% CI: 1.29–1.47, p < 0.0001). Finally, the cumulative inci-
dence rate of acute surgery increased with increasing
suPAR (Fig. 2).
suPAR in acute and elective surgery
When comparing acute with elective surgery, suPAR was
increased in patients undergoing endoscopies, gastro-
enterological-, orthopedic-, respiratory-, urological- and,
to a lesser degree, dermatological- and cancer-related
surgical procedures (Table 3).
Mortality rates in acute medical patients
In the entire population of acutely admitted medical
patients, mortality rates were higher among those who
received acute surgery during follow-up compared with
non-surgical patients, whereas mortality rates were simi-
lar among patients receiving elective surgery compared
with the non-surgical patients (Table 2).
90-day post-operative mortality was higher in patients
receiving acute surgery compared to elective in the
majority of specialties (Table 3). This increased mortality
was particularly evident for gastroenterological-, ortho-
pedic-, respiratory-, vascular-, and cancer-related surgery
as well as endoscopies, but also observed for cardiothor-
acic-, neurological-, urological-, minor-, and dermatological
surgical procedures (Table 3).
suPAR is associated with post-operative mortality in
acutely operated patients
Of the patients receiving acute surgery, 439 died (18.3%)
within 90 days follow-up after surgery. In Cox regression
analysis adjusted for sex, age, CRP, and Charlson score,
the HR for 90-day post-operative mortality for doubling
the suPAR value was 1.73 (95% CI: 1.52–1.95, p <
0.0001). Due to variability in time from the index admis-
sion to the acute surgical procedure, we tested for an
interaction between the suPAR level and time from
suPAR analysis to surgery in the Cox regression analysis
for 90-day post-operative mortality, and found no
Table 1 Baseline characteristics of acutely admitted medical
patients at the index admission
Characteristics Patients (n = 17,312)
Male sex, n (%) 8118 (47)
Age (years), median (IQR) 61.3 (43.3–76.3)
CRP (mg/l), median (IQR) 5 (1–31)
suPAR (ng/ml), median (IQR) 2.8 (1.9–4.3)
Charlson score, median (IQR) 0 (0–1)
CRP C-reactive protein, IQR interquartile range, suPAR soluble urokinase
plasminogen activator receptor
Table 2 Acutely admitted medical patients stratified in relation to surgery
Characteristics No surgery (n = 13,544) Acute surgery (n = 2404) p-valuea Elective surgery (n = 1364) p-valueb
Male sex, n (%) 6308 (46.6) 1113 (46.3) 0.80 697 (51.1) 0.0014
Age, median (IQR) 60.0 (41.8–76.1) 66.4 (47.4–78.8) < 0.0001 64.9 (51.7–74.5) < 0.0001
CRP, median (IQR) 5 (1–26) 12 (3–61) < 0.0001 5 (1–22) 0.30
suPAR, median (IQR) 2.7 (1.9–4.0) 3.6 (2.4–5.7) < 0.0001 2.9 (2.1–4.2) < 0.0001
Charlson score, median (IQR) 0 (0–1) 0 (0–2) < 0.0001 0 (0–1) < 0.0001
Mortality rate per person-year 0.12 0.37 < 0.0001 0.13 0.60
CRP C-reactive protein, IQR interquartile range, suPAR soluble urokinase plasminogen activator receptor
aAcute surgery compared to no surgery
bElective surgery compared to no surgery
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interaction (p = 0.86). The 90-day post-operative mortal-
ity after acute surgery was higher for patients with ele-
vated baseline levels of suPAR (Fig. 3).
Discussion
In this large cohort of acute medical patients, 14%
underwent acute surgery during a median follow-up of
little more than a year. Elevated suPAR levels were
significantly associated with increased risk of future
acute surgery as well as postoperative mortality when
adjusted for sex, age, CRP, and comorbidity burden. To
our knowledge, this study is the first to investigate an
association between suPAR in patients admitted with an
acute medical condition and the risk of receiving future
acute surgery.
suPAR is a prognostic biomarker routinely measured
in acute medial patients in our hospital. It has previously
been shown that elevated suPAR level is associated with
increased risk of admission to the intensive care unit,
readmissions, and mortality in these patients [1, 8, 20].
In this study, we add the risk of future acute surgery to
the list of negative outcomes associated with elevated
suPAR level.
There is a limited amount of research that has used
acute surgery as an outcome measurement, and the use
of biomarkers for risk prediction in surgery is generally
directed towards predicting post-operative outcomes,
such as morbidity and mortality [24, 25]. A British study
found associations between increasing CRP levels during
admittance and the risk of undergoing acute surgery in
patients presenting with acute renal colic. However,
there was no association between the initial admission-
level of CRP and the risk of acute surgery [26].
In contrast, we found that the initial suPAR level was
associated with the risk of future acute surgery in an
unspecific cohort of acute medical patients. This know-
ledge of the relation between suPAR and future acute
surgery cannot be used to exactly predict which acute
medical patients will undergo acute surgery, but it adds
acute surgery as an adverse event to be aware of, when
encountering patients with elevated levels of suPAR.
Elevated suPAR at the index admission was also found
to be associated with future post-operative mortality.
The mortality rate was higher in patients receiving acute
surgery compared with both patients receiving elective
and no surgery. To support this, earlier studies also
showed increased mortality among acutely operated
patients compared with elective patients [2–4]. Similarly,
preoperative suPAR levels was shown to be an independ-
ent predictor of mortality in patients operated for
colorectal cancer [27]. The observation that suPAR car-
ries information on post-operative mortality suggests
that suPAR could potentially supplement preoperative
risk scoring systems, such as the American Society of
Anaesthesiologists (ASA) score [28] or raise attention to
high-risk patients prior to surgery.
In the cohort, the suPAR levels were significantly
elevated among both patients receiving acute and elect-
ive surgery compared to patients receiving no surgery;
the highest suPAR levels were observed in acutely oper-
ated patients. The acute surgical patients were more ill,
as indicated by the presence of comorbidities and higher
suPAR levels. Similarly, a large American study of
surgical patients also observed a higher proportion of
patients with preoperative systemic inflammatory re-
sponse syndrome or sepsis and thereby higher preopera-
tive inflammation level among acutely operated patients
[3]. Even though there are differences between our study
and the American study, both studies find that preopera-
tive inflammation and comorbidities have an effect on
the post-operative outcome [3].
suPAR was analyzed at a median of 74 days before sur-
gery, indicating that it reflects an underlying pathology
or frailty that increase the risk of acute surgery. It raises
the question of whether suPAR measured immediately
before surgery could have even stronger post-operative
prognostic value. This was not possible to determine
with the present study design.
Our study finds that suPAR can serve as an ‘attention
marker’ for identifying the most fragile acute medical
patients who have the highest risk of negative outcomes,
including acute surgery.
Fig. 2 Cumulative incidence plot of patients’ risk of acute surgery
stratified by suPAR concentrations. Competing risks are death and
elective surgery. Inset: zoom on the first 30-day interval is shown.
suPAR 0–3 ng/ml included 9720 (56.2%) patients, suPAR 3–6 ng/ml
included 5537 (32.0%) patients, suPAR 6–9 ng/ml included 1299 (7.5%)
patients, and suPAR >9 ng/ml included 756 (4.4%) patients. Log-rank
test showed p < 0.0001. suPAR, soluble urokinase plasminogen
activator receptor
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Limitations
This study has some limitations. The study was carried
out at a single hospital and should be reproduced in a
multicenter study to improve general applicability. In
our hospital, acutely admitted gastroenterological pa-
tients, children, and obstetric patients are admitted
through specialized acute departments, where suPAR is
not routinely analyzed; therefore, these patients were not
included in the study. Another limitation is the lack of
data on smoking habits, which has been shown to
increase suPAR levels with up to 1–2 ng/ml in the
general population [29].
The types of surgery could have been stratified into
risk levels in relation to post-operative mortality as the
specific type of surgery has a large influence on post-
operative mortality [30] and may be a potential con-
founder. A second analysis excluding minor surgery
(ascites puncture, needle biopsies etc.) and endoscopies
showed that the prognostic effect of suPAR is not
limited to minor surgical procedures.
Conclusion
In summary, we found that elevated suPAR levels in
acute medical patients were associated with increased
risk of future acute surgery and of post-operative mortal-
ity. The suPAR biomarker may, along with other bio-
markers and clinical observations, aid the physicians in
identifying acute medical patients in high risk of nega-
tive outcomes.
Abbreviations
AMU: Acute medical unit; ASA: American Society of Anaesthesiologists;
CI: Confidence interval; CPR: Civil registration number; CRP: C-reactive
protein; HR: Hazard ratio; ICD: International Classification of Diseases;
IQR: Interquartile range; NPR: National Patient Registry; SKS: Danish national
Healthcare Classification System; suPAR: Soluble urokinase plasminogen
activator receptor
Table 3 Acute and elective surgery in individual specialties
Acute surgery Elective surgery
Type of surgery n (%)a Median suPAR 90-days mortality:
n (%)
n Median suPAR 90-days mortality:
n (%)
p-value suPARb p-value mortalityc
Gastroenterological 353 (68.7) 3.7 75 (21.3) 161 3.2 9 (5.6) 0.0032 < 0.0001
Orthopedic 320 (57.7) 4.3 61 (19.1) 235 2.8 5 (2.1) < 0.0001 < 0.0001
Cardiothoracic 111 (30.3) 2.8 8 (7.2) 255 2.6 3 (1.2) 0.16 0.0041d
Neurological 68 (44.7) 2.9 8 (11.8) 84 2.8 2 (2.4) 0.90 0.043d
Respiratory 357 (86.9) 4.4 131 (36.7) 54 3.1 5 (9.3) < 0.0001 < 0.0001
Urological 87 (41.6) 4.4 14 (16.1) 122 3.1 5 (4.1) < 0.0001 0.0029
Minor 381 (87.0) 4.5 114 (29.9) 57 3.8 4 (7.0) 0.065 0.0003
Endoscopies 764 (76.7) 4.2 145 (19.0) 230 3.3 11 (4.8) < 0.0001 < 0.0001
Gynecological 34 (34.7) 2.8 1 (2.9) 64 2.7 0 0.53 0.17
Obstetrics 231 (89.1) 1.6 0 28 1.8 0 0.50
Vascular 54 (36.7) 4.1 12 (22.2) 93 4.2 1 (1.1) 0.96 < 0.0001
Dermatological 161 (80.5) 4.1 29 (18.0) 39 3.7 1 (2.6) 0.022 0.0153d
Other 10 (10.5) 2.5 1 (10.0) 85 2.8 2 (2.4) 0.71 0.19
Cancer-relatede 104 (40.5) 4.1 46 (44.2) 153 3.4 11 (7.2) 0.010 < 0.0001
suPAR soluble urokinase plasminogen activator receptor
aThe percentage of total surgery in the specific specialty
bp-value is calculated for suPAR in acutely vs. electively operated patients
cp-value is calculated for acute 90-day mortality compared with elective 90-day mortality
dFisher’s exact test is used instead of Pearson’s Chi-squared test
eCancer-related surgery is measured as the patient having cancer as the main diagnosis when surgery was performed
Fig. 3 Kaplan-Meier plot of 90-day post-operative mortality in
acutely operated patients, stratified on suPAR concentrations. suPAR
0–3 ng/ml included 955 (39.7%) patients, suPAR 3–6 included 921
(38.3%) patients, suPAR 6–9 included 320 (13.3%) patients, and
suPAR >9 included 208 (8.7%) patients. Log-rank test showed p <
0.0001. suPAR, soluble urokinase plasminogen activator receptor
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